Lars Lofgren
BioPharmaceuticals R&D
Goeteborg, O 43183, Sweden
Goeteborg, O 43183, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression.
Journal: Cardiovascular research
Published: January 14, 2026
Systematic Application of a Cellular Thermal Shift Assay for Inferring Inhibitor Binding Affinity to 17βHSD13 in a Humanized Liver Homogenate.
Journal: Biochemistry
Published: January 12, 2026
Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model.
Journal: Pharmacological research
Published: March 03, 2025
Shifting participatory approach when ideology meets reality: a grounded theory study based on project leaders' experiences with peer-led sex education programs for and by persons with intellectual disabilities and/or autism.
Journal: Reproductive health
Published: September 13, 2024
Patient-Centric Quantitative Microsampling for Accurate Determination of Urine Albumin to Creatinine Ratio (UACR) in a Clinical Setting.
Journal: The journal of applied laboratory medicine
Published: April 13, 2023
Associations of Biopterins and ADMA with Vascular Function in Peripheral Microcirculation from Patients with Chronic Kidney Disease.
Journal: International journal of molecular sciences
Published: February 24, 2023
Elevated Adipocyte Membrane Phospholipid Saturation Does Not Compromise Insulin Signaling.
Journal: Diabetes
Published: March 28, 2022
TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis.
Journal: Nature communications
Published: January 05, 2022
Metabolomic Profile in HFpEF vs HFrEF Patients.
Journal: Journal of cardiac failure
Published: February 24, 2020
Development of a highly sensitive liquid chromatography-mass spectrometry method to quantify plasma leukotriene E4 and demonstrate pharmacological suppression of endogenous 5-LO pathway activity in man.
Journal: Prostaglandins & other lipid mediators
Published: December 19, 2019
Last Updated: 09/26/2026